Search
Search
About
Log in
Join
Experiences with
Triple Sulfa
Posts
Communities
5,178 public posts
Filter results
Leukemia-associated macrophages, their role in the CLL Tumor Micro-environment and how they affect progression and therapy response
Understanding how the CLL Tumor Micro-environment (TME) functions is crucial to improving CLL therapy. CLL cells are not as robust as healthy B cells and they rely on their created TME in the nodes and bone marrow for their survival. That's why it's so easy to kill CLL cells with in vitro testing - checking
Understanding how the CLL Tumor Micro-environment (TME) functions is crucial to improving CLL therapy. CLL cells are not as robust as healthy B cells and they rely on their created TME in the nodes and bone marrow for their survival. That's why it's so easy to kill CLL cells with in vitro testing - checking
AussieNeil
Partner
in
CLL Support
2 days ago
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
»The variant allele frequency (VAF) of driver mutations (JAK2, CALR) in myeloproliferative neoplasms is associated with features of advanced disease and complications. Ruxolitinib and interferon were reported to variably reduce the mutant VAF, but the long-term impact of molecular responses (MR) remains
»The variant allele frequency (VAF) of driver mutations (JAK2, CALR) in myeloproliferative neoplasms is associated with features of advanced disease and complications. Ruxolitinib and interferon were reported to variably reduce the mutant VAF, but the long-term impact of molecular responses (MR) remains
Manouche
in
MPN Voice
3 days ago
Terbium-161 - As a follow-up to Alicia Morgan's comments in the PeterMac GUcast interview posted earlier by marnie46.
I meant to include this article, a 24 Nov 2023 news release on Terbium-161, in a followup reply to Marnie's post of the Dr. Morgan interview by the excellent PeterMac team several days back. [i]
Three big challenges in metastatic prostate cancer | Dr Alicia Morgans
[/i] [i]
https://healthunlocked.com
I meant to include this article, a 24 Nov 2023 news release on Terbium-161, in a followup reply to Marnie's post of the Dr. Morgan interview by the excellent PeterMac team several days back. [i]
Three big challenges in metastatic prostate cancer | Dr Alicia Morgans
[/i] [i]
https://healthunlocked.com
cujoe
in
Fight Prostate Cancer
4 days ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Important from The PBC Foundation....
We are asking for your help. 4/6/2024 Very directly. Very succinctly. We need your help. This is the most important thing the Foundation has ever worked on: more important than the surveys, more important than the helpline, more important than the name change. We are writing a letter which we
We are asking for your help. 4/6/2024 Very directly. Very succinctly. We need your help. This is the most important thing the Foundation has ever worked on: more important than the surveys, more important than the helpline, more important than the name change. We are writing a letter which we
DonnaBoll
Administrator
in
PBC Foundation
4 days ago
Genetic background strongly influences the impact of carrying the Thr92Ala-DIO2 polymorphism in the male mouse
Are you male? Are you a mouse? Do you carry the Thr92Ala-DIO2 allele? Can you wait for the publication of this paper? Can you wait for the human version of this trial? And do you consider it necessary to wait for the eventual publication of the human trial before considering T3? It is undoubtedly
Are you male? Are you a mouse? Do you carry the Thr92Ala-DIO2 allele? Can you wait for the publication of this paper? Can you wait for the human version of this trial? And do you consider it necessary to wait for the eventual publication of the human trial before considering T3? It is undoubtedly
helvella
Thyroid UK
in
Thyroid UK
5 days ago
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
For those of you who might be interested... MALVERN, Pa. June 5, 2024 -- Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease
For those of you who might be interested... MALVERN, Pa. June 5, 2024 -- Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease
Canddy
in
Cure Parkinson's
5 days ago
Phase 1/2 ARV-766 clinical trial
“The purpose of this study is to assess the safety and tolerability (good and bad effects) and how prostate cancer responds to two different doses of the investigational study drug (ARV-766) in combination with Abiraterone in men with metastatic cRPC who have not received prior novel hormonal therapies
“The purpose of this study is to assess the safety and tolerability (good and bad effects) and how prostate cancer responds to two different doses of the investigational study drug (ARV-766) in combination with Abiraterone in men with metastatic cRPC who have not received prior novel hormonal therapies
Woodman33
in
Advanced Prostate Cancer
6 days ago
FDA Greenlights Phase 2/3 Trial of KPG-121/Abiraterone in mCRPC
A clinical trial to evaluate the combination of a new drug called KPG-121 with abiraterone acetate (Zytiga) for treating metastatic castration-resistant prostate cancer (mCRPC) as a first-line therapy has been approved by the FDA. KPG-121 is an investigational drug that targets specific proteins involved
A clinical trial to evaluate the combination of a new drug called KPG-121 with abiraterone acetate (Zytiga) for treating metastatic castration-resistant prostate cancer (mCRPC) as a first-line therapy has been approved by the FDA. KPG-121 is an investigational drug that targets specific proteins involved
God_Loves_Me
in
Advanced Prostate Cancer
6 days ago
Denmeade on identifying patients who may benefit from BAT
Dr. Denmeade concluded his presentation with the following key takeaways: The presence of AR alterations in ctDNA may identify patients who may or may not benefit from BAT In this study patients with no AR alterations treated with BAT exhibit significantly shorter PFS and OS compared to those treated
Dr. Denmeade concluded his presentation with the following key takeaways: The presence of AR alterations in ctDNA may identify patients who may or may not benefit from BAT In this study patients with no AR alterations treated with BAT exhibit significantly shorter PFS and OS compared to those treated
cigafred
in
Fight Prostate Cancer
6 days ago
Long Covid three years on, and what Covid 19 has planned for Q3-4/ 24
This long and informative article https://erictopol.substack.com/p/long-covid-at-3-years co-presented by Eric Topol and Ziyad Al-Aly, majors on two new studies on health outcomes for large numbers of early COVID-19 patients who were followed up for three years. The VA study in > 135,000 people showed
This long and informative article https://erictopol.substack.com/p/long-covid-at-3-years co-presented by Eric Topol and Ziyad Al-Aly, majors on two new studies on health outcomes for large numbers of early COVID-19 patients who were followed up for three years. The VA study in > 135,000 people showed
bennevisplace
in
CLL Support
11 days ago
FDA clearance for SYNC-T SV-102, a pioneering combo immunotherapy for Metastatic Castrate-Resistant Prostate Cancer
Source link: https://finance.yahoo.com/news/syncromune-inc-announces-fda-clearance-232200345.html SYNC-T SV-102 Therapy combines partial tumor oncolysis with a fixed-dose combination multi-target biologic drug to provide a novel, personalized therapeutic approach for the treatment of metastatic
Source link: https://finance.yahoo.com/news/syncromune-inc-announces-fda-clearance-232200345.html SYNC-T SV-102 Therapy combines partial tumor oncolysis with a fixed-dose combination multi-target biologic drug to provide a novel, personalized therapeutic approach for the treatment of metastatic
God_Loves_Me
in
Advanced Prostate Cancer
11 days ago
Piperine and L-dopa producing probiotic
I recently ran across a couple of things about gut bacteria that I thought were interesting. The first involves the use of piperine (an extract of black pepper) to keep l-dopa from being converted to dopamine by bacteria in the small intestine, leaving more to travel to the brain; https://onlinelibrary.wiley.com
I recently ran across a couple of things about gut bacteria that I thought were interesting. The first involves the use of piperine (an extract of black pepper) to keep l-dopa from being converted to dopamine by bacteria in the small intestine, leaving more to travel to the brain; https://onlinelibrary.wiley.com
Rufous2
in
Cure Parkinson's
11 days ago
pleural effusion
hi all you very supportive ladies . 4 years since my diagnosis with stage 3 ovarian cancer I have had all the chemo combinations available plus Avastin and PARP inhibitors . I was then in a clinical trial for a year which had a small effect and finished in March. a couple of weeks ago , I was admitted
hi all you very supportive ladies . 4 years since my diagnosis with stage 3 ovarian cancer I have had all the chemo combinations available plus Avastin and PARP inhibitors . I was then in a clinical trial for a year which had a small effect and finished in March. a couple of weeks ago , I was admitted
Lookingahead
in
My Ovacome
12 days ago
Aspen Neuroscience to Present at International Society for Cell & Gene Therapy (ISCT) Annual Meeting
As part of the ISCT 2024 Translational Pathway Sessions, as well as the ISCT main program, Aspen's Chief Scientific Officer Xiaokui Zhang, Ph.D., and Chief Technology Officer Kim Raineri will discuss developments in autologous research and development, including for ANPD001, Aspen's autologous iPSC-derived
As part of the ISCT 2024 Translational Pathway Sessions, as well as the ISCT main program, Aspen's Chief Scientific Officer Xiaokui Zhang, Ph.D., and Chief Technology Officer Kim Raineri will discuss developments in autologous research and development, including for ANPD001, Aspen's autologous iPSC-derived
Farooqji
in
Cure Parkinson's
12 days ago
PROTACS: what they are and the good and bad of these molecules
Fascinating, and they are currently being tested also for degenerative diseases...they are a rather new technique...and yet we already have "advanced PROTACs", the speed of research is impressive... 1. PROTAC Mechanism Proteolysis-targeting chimeras (PROTACs) have emerged as a promising therapeutic
Fascinating, and they are currently being tested also for degenerative diseases...they are a rather new technique...and yet we already have "advanced PROTACs", the speed of research is impressive... 1. PROTAC Mechanism Proteolysis-targeting chimeras (PROTACs) have emerged as a promising therapeutic
Maxone73
in
Advanced Prostate Cancer
12 days ago
News from Malecare and OpenAI
Today, GPTs in the Store are now available to all ChatGPT users, allowing more than 100 million weekly active users to experience Cancer Copilot, Clinical Trial Navigator and the others in the store for free. Also, GPTs now use the newest flagship model, GPT-4o. Here are direct links: https://chatgpt.com
Today, GPTs in the Store are now available to all ChatGPT users, allowing more than 100 million weekly active users to experience Cancer Copilot, Clinical Trial Navigator and the others in the store for free. Also, GPTs now use the newest flagship model, GPT-4o. Here are direct links: https://chatgpt.com
Darryl
Partner
in
Prostate Cancer Network
13 days ago
news from Malecare and OpenAI
Today, GPTs in the Store are now available to all ChatGPT users, allowing more than 100 million weekly active users to experience Cancer Copilot, Clinical Trial Navigator and the others in the store for free. Also, GPTs now use the newest flagship model, GPT-4o. Here are direct links: https://chatgpt.com
Today, GPTs in the Store are now available to all ChatGPT users, allowing more than 100 million weekly active users to experience Cancer Copilot, Clinical Trial Navigator and the others in the store for free. Also, GPTs now use the newest flagship model, GPT-4o. Here are direct links: https://chatgpt.com
Darryl
Partner
in
Advanced Prostate Cancer
13 days ago
Wednesday's Word
[u][i]
Second line therapy
[/i][/u] [u][i][/i][/u]
This a term used In PBC a patient does not respond to Urso - usually within a year's time from the start of dosing. A different drug of choice is needed.
The only approved second line treatment is the use of Ovaliva (obeticholic acid
[u][i]
Second line therapy
[/i][/u] [u][i][/i][/u]
This a term used In PBC a patient does not respond to Urso - usually within a year's time from the start of dosing. A different drug of choice is needed.
The only approved second line treatment is the use of Ovaliva (obeticholic acid
DonnaBoll
Administrator
in
PBC Foundation
13 days ago
Interactive seminar on Garvan institute's work to improve the treatment of advanced cancers, including myeloma, breast and prostate cancer
Garvan Institute of Medical Research Free Public Seminar - Giving cancer no place to hide SPEAKER/S Professor Peter Croucher and Associate Professor Christine Chaffer DATE 10:30am 21 Jun 2024— 11:30am 21 Jun 2024 (AEST) Join us for an interactive seminar on Garvan’s work to improve the treatment
Garvan Institute of Medical Research Free Public Seminar - Giving cancer no place to hide SPEAKER/S Professor Peter Croucher and Associate Professor Christine Chaffer DATE 10:30am 21 Jun 2024— 11:30am 21 Jun 2024 (AEST) Join us for an interactive seminar on Garvan’s work to improve the treatment
Seasid
in
Advanced Prostate Cancer
13 days ago
Statins in older patients and their benefits
There is, not surprisingly, a lot of discussion here about us taking statins and one of the points often made is that there has been little evidence of benefit for over 75s - mainly because they are more often than not excluded from clinical trials. This is a patient summary of a Chinese study which
There is, not surprisingly, a lot of discussion here about us taking statins and one of the points often made is that there has been little evidence of benefit for over 75s - mainly because they are more often than not excluded from clinical trials. This is a patient summary of a Chinese study which
PMRpro
Ambassador
in
PMRGCAuk
14 days ago
1
2
...
100
Next page
10
20
30
40
50
60
70
80
90
100
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1279 results
Cure Parkinson's
646 results
CLL Support
623 results
View top 10 communities
Sort by
Most Relevant
Newest